MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it will be featuring its perioperative suite of innovative products including MediClear™ PreOp at the Association of periOperative Registered Nurse’s (AORN) Surgical Conference and Expo, the largest international gathering of perioperative registered nurses worldwide.
MediClear™ PreOp is the market’s first breathable and transparent Antimicrobial Self-Adherent Silicone Drape for PreOperative Skin. Its polyurethane barrier film acts as a protective barrier to isolate a procedural site from external contamination, and its silicone adhesive provides a rapid bactericidal and fungicidal effect against a broad spectrum of microorganisms, averaging a 99.99% reduction after 30 minutes, and preventing their regrowth for up to seven days during wear.
"This is an exciting time for our perioperative line-up of products," said John R. Hands, Covalon’s Executive Vice President of Marketing. "With the United States Food and Drug Administration clearance of MediClear PreOp, our products are now truly able to follow the patient through their surgical ‘life cycle’, giving their health care providers the confidence that they are using state-of-the-art technology to help in the fight against surgical site infections. We are confident that MediClear PreOp will add enormous value to healthcare systems, clinicians and of course patients through improved outcomes,” he continued.
Covalon will also be showcasing its unique line of self-adherent silicone products that aid in the management of the surgical incision. These include SurgiClear™, a dual antimicrobial transparent dressing proven to have a synergistic effect against some of the most common surgical site infection bacteria1, and MediClear Scar™, a single-use, discreet film dressing designed to help prevent, manage, and reduce the severity of an incision scar.
Visit Covalon at booth 2814 at the AORN Surgical Conference and Expo during exhibit hours between March 25-27, at the Ernest N. Morial Convention Center in New Orleans, LA.
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
1 A Laboratory Study of the Synergistic Effect of Chlorhexidine and Silver, Blom, Kristina Werthen, Maria et al.American Journal of Infection Control , Volume 43 , Issue 6 , S22